117 related articles for article (PubMed ID: 38053514)
1. CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study.
Huang Y; Jia Y; Chen X; Wang C; Wang Y; Wang M; Wu P; Shen J
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):1005-1013. PubMed ID: 38053514
[TBL] [Abstract][Full Text] [Related]
2. The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects.
Li T; Li X; Jiang X; Wang C; Sun F; Liu Y; Lin P; Shi P; Fu Y; Gao X; Zhang Y; Cao Y
Cancer Chemother Pharmacol; 2022 Nov; 90(5):409-415. PubMed ID: 36107220
[TBL] [Abstract][Full Text] [Related]
3. Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects.
Hu L; Cai M; Qian W; Dou T; Sun Q; Tang L; Wang H
Invest New Drugs; 2022 Dec; 40(6):1274-1281. PubMed ID: 36087164
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
Mu S; Lin C; Skrzypczyk-Ostaszewicz A; Bulat I; Maglakelidze M; Skarbova V; Andreu-Vieyra C; Sahasranaman S
Cancer Chemother Pharmacol; 2021 Jul; 88(1):81-88. PubMed ID: 33772633
[TBL] [Abstract][Full Text] [Related]
5. Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects.
Hu L; Dou T; Sun Q; Tang L; Cai M; Qian W; Wang H
Invest New Drugs; 2023 Apr; 41(2):276-283. PubMed ID: 36800130
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J
Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634
[TBL] [Abstract][Full Text] [Related]
7. Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects.
Tachibana M; Matsuki S; Maekawa Y; Kuroda K; Shimizu T; Tsutsumi J; Ishizuka H
Clin Transl Sci; 2023 Nov; 16(11):2153-2162. PubMed ID: 37705321
[TBL] [Abstract][Full Text] [Related]
8. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
[TBL] [Abstract][Full Text] [Related]
9. Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers.
Hu C; Zhang Y; Pei T; Liu P; Zhang L
Cancer Chemother Pharmacol; 2023 Jun; 91(6):523-529. PubMed ID: 37166499
[TBL] [Abstract][Full Text] [Related]
10. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.
Mu S; Tang Z; Novotny W; Tawashi M; Li TK; Ou Y; Sahasranaman S
Cancer Chemother Pharmacol; 2020 Feb; 85(2):391-399. PubMed ID: 31875923
[TBL] [Abstract][Full Text] [Related]
11. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
[TBL] [Abstract][Full Text] [Related]
13. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
[TBL] [Abstract][Full Text] [Related]
14. Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers.
Zhu YT; Zhang YF; Jiang JF; Yang Y; Guo LX; Bao JJ; Zhong DF
Invest New Drugs; 2021 Aug; 39(4):1011-1018. PubMed ID: 33506323
[TBL] [Abstract][Full Text] [Related]
15. Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers.
Liu L; Li W; Yang L; Guo ZT; Xue H; Xie NJ; Chen XY
Acta Pharmacol Sin; 2022 Apr; 43(4):1082-1090. PubMed ID: 34267345
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers.
Heng J; Tang Q; Chen X; Bao J; Deng J; Chen Y; Zhao J; Zhu S; Liu X; Yang F; Jiang Y; Yang N; Li K
Eur J Pharm Sci; 2021 Jul; 162():105815. PubMed ID: 33771716
[TBL] [Abstract][Full Text] [Related]
17. Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor.
Desch M; Wunderlich G; Goettel M; Goetz S; Liesenfeld KH; Chan TS; Rosenbrock H; Sennewald R; Link J; Keller S; Wind S
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):91-103. PubMed ID: 34716565
[TBL] [Abstract][Full Text] [Related]
18. Effect of CYP3A4 induction and inhibition on the pharmacokinetics of SHR0302 in healthy subjects.
Zhang Z; Gao X; Zhang P; Li Y; Fu M; Lin H; Feng S; Shen K; Yu G; Li X
Br J Clin Pharmacol; 2023 Aug; 89(8):2561-2568. PubMed ID: 37005376
[TBL] [Abstract][Full Text] [Related]
19. Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.
Ogasawara K; MacGorman K; Liu L; Chen J; Carayannopoulos LN; Zhou S; Palmisano M; Li Y
J Clin Pharmacol; 2019 Dec; 59(12):1620-1631. PubMed ID: 31172535
[TBL] [Abstract][Full Text] [Related]
20. Effects of Strong Inhibition of Cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and Strong Induction of Cytochrome P450 3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two Drug-Drug Interaction Studies in Healthy Volunteers.
Yin W; Dong C; Stevenson A; Lloyd V; Petrillo M; Baratta M; Hui T; Han S
Drug Metab Dispos; 2024 Feb; 52(3):180-187. PubMed ID: 38123352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
